The FY2025 (Dec) proxy of Kymera Therapeutics names 18 peer companies for pay. Among Kymera Therapeutics and these peers, CEO pay was 7th highest of 10 and total shareholder return was 7th highest of 10.
7th highest of 10in Kymera Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$4.8M$33.3M
7th highest of 10in Kymera Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$20$625
Pay peer group, FY2025 (Dec) proxy
| Scholar Rock Holding | ||
| Viking Therapeutics | ||
| Revolution Medicines | ||
| Protagonist Therapeutics | ||
| Immunovant | ||
| IDEAYA Biosciences | ||
| Vera Therapeutics | ||
| Beam Therapeutics | ||
| Denali Therapeutics | ||
| ApogeeTherapeutics | Not disclosed | Not disclosed |
| Arcellx | Not disclosed | Not disclosed |
| Arvinas | Not disclosed | Not disclosed |
| Avidity Biosciences | Not disclosed | Not disclosed |
| Biohaven | Not disclosed | Not disclosed |
| Dyne Therapeutics | Not disclosed | Not disclosed |
| ImmunityBio | Not disclosed | Not disclosed |
| Nuvalent | Not disclosed | Not disclosed |
| Vaxcyte | Not disclosed | Not disclosed |
18 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.